[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-357475-105":59,"doc-detail-357475-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","scalable-engineering-of-bio-manufactured-extracellular-vesicles-for-selective-delivery-in-ovarian-cancer-patient-derived-models","Scalable Engineering of Bio-Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient-Derived Models","","Ovarian cancer remains difficult to treat due to late diagnosis, tumor heterogeneity, and limited effectiveness of current therapies. The work presents a streamlined, scalable extracellular vesicle (EV) engineering platform that improves cargo packaging and enables selective in vivo delivery to ovarian tumors. The study compares vesicle anchoring domains, defines an optimized scaffold for bioluminescent cargo loading, and generates robust large-scale engineered EVs from stably engineered ExpiCHO cells. Targeting is achieved by modifying the Δ688 PTGFRN scaffold to display Ephrin-B2 (EB2) for high-affinity binding to EphB4. After systemic administration, the engineered EVs preferentially accumulate in EphB4-positive cells, support non-invasive spatiotemporal bioluminescence tracking, and show selective localization and intratumoral cargo reporting in patient-derived xenografts.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/scalable-engineering-of-bio-manufactured-extracellular-vesicles-for-selective-delivery-in-ovarian-cancer-patient-derived-models/357475/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/scalable-engineering-of-bio-manufactured-extracellular-vesicles-for-selective-delivery-in-ovarian-cancer-patient-derived-models/357475.png","ImageObject",300,407,{"name":92,"@type":93},"Well Done","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is targeted extracellular vesicle delivery important for ovarian cancer?","Question",{"text":112,"@type":113},"Ovarian cancer is difficult to treat because of late detection, heterogeneity, and inadequate delivery of therapies to advanced tumors. The document emphasizes that off-target toxicity, rapid systemic clearance, and poor accumulation limit conventional approaches.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How does the engineered EV system achieve molecular targeting?",{"text":117,"@type":113},"The approach modifies the transmembrane scaffold Δ688 PTGFRN to display the tissue-targeting ligand Ephrin-B2 (EB2). This enables high-affinity interaction with Eph receptor B4 (EphB4), which is overexpressed in advanced ovarian carcinoma.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence of selective delivery is reported in the patient-derived xenograft models?",{"text":121,"@type":113},"In xenografts with differential EphB4 expression, Ephrin-B2–displaying engineered EVs show selective localization to EphB4-positive tumors and can report intratumoral cargo distribution using bioluminescence tracking.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},357475,1790858755,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},5909892210082,"https://ap-avatar.wpscdn.com/avatar/56001069da27c9f41e8?x-image-process=image/resize,m_fixed,w_180,h_180&k=1789614185077863061","Advanced Science    \n[www.advancedscience.com](www.advancedscience.com)  \n RESEARCH ARTICLE   \nScalable Engineering of Bio-Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient-Derived Models  \nNihar Godbole1, 2   Andrew Lai1, 2  Alexander Quinn3, 4  Marianne Gillard5 Katherin Scholz-Romero1, 2  Alexis Salas-Burgos6, 7  Bastián Lillo Dapremont6, 7 Richard Lobb5  Kate Beecher4   Amy E. McCart Reed4  Kaltin Ferguson9 John D. Hooper7   Carlos Salomon1, 2   \n Dominic Guanzon1, 2    \n Rohan Lourie8, 9  Naven Chetty8  Biao Sun9  Yaowu He9   \n1Translational Extracellular Vesicles in Obstetrics and Gynae-Oncology Group, Frazer Institute, Faculty of Health Medicine and Behavioural Sciences, Royal Brisbane and Women’s Hospital, The University of Queensland, Herston, Queensland, Australia  2UQ Centre for Extracellular vesicle Nanomedicine, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Herston, Queensland, Australia  3 Commonwealth Scientific and Industrial Research Organisation, Agriculture & Food, Saint Lucia, Queensland, Australia  4 Frazer Institute, Faculty of Health, Medicine and Behavioural Sciences, The University of Queensland, Herston, Queensland, Australia  5Australian Institute for Bioengineering and Nanotechnology (AIBN), The University of Queensland, Brisbane, Queensland4072, Australia  6 Oncology Progression Laboratory, Pharmacology Department, Biological Science Faculty, Concepcion University, Concepción, Chile  7 Centro Territorial de Investigación Oncológica Integrativa (CTIOi), Santiago, Chile  8Mater Health Services, South Brisbane,  \nQueensland, Australia  9Mater Research Institute, Translational Research Institute, University of Queensland, Woolloongabba, Queensland, Australia Correspondence: Carlos Salomon ([c.salomongallo@uq.edu.au](c.salomongallo@uq.edu.au))  \nReceived: 5 February 2026  Revised: 27 March 2026  Accepted: 13 April 2026  \nABSTRACT  \nOvarian cancer remains challenging to treat because of late diagnosis, heterogeneity, and poor response to existing therapies. Here, we present a streamlined and scalable extracellular vesicle (EV) engineering approach that enables efficient cargo packaging and enhances targeted cargo delivery to ovarian tumors in vivo. Systematic comparison of vesicle-anchoring domains identifies an optimized scaffold for loading bioluminescent cargo into EVs. We characterized EV production from five cell lines commonly used for biopharmaceutical manufacturing and selected and stably engineered ExpiCHO cells as a robust, large-scale source of engineered EVs (eEVs). To achieve molecular targeting, the transmembrane scaffold Δ688 PTGFRN is modified to display tissuetargeting ligand Ephrin-B2 (EB2) on the EV surface, exploiting its high-affinity interaction with the Eph receptor B4 (EphB4), which is overexpressed in advanced ovarian carcinoma. Following systemic administration, these eEVs carrying bioluminescent cargo preferentially accumulate in EphB4-positive cells in vivo and permit non-invasive, spatiotemporal tracking via cargomediated bioluminescence resonance energy transfer. In patient-derived xenograft models with differential EphB4 expression, Ephrin-B2–displaying eEVs show selective localization to EphB4-positive tumors and report intratumoral cargo distribution. This work establishes a translational strategy for large-scale eEV production, advancing EV-based delivery platforms for precision targeting of EphB4-expressing ovarian cancer.  \n1  Introduction  \nOvarian cancer remains the sixth leading cause of cancerrelated mortality among women worldwide, primarily due to  \nits late detection, recurrence, and treatment resistance [1, 2] . Conventional therapies have improved survival outcomes inpatients with early-stage disease; however, their effectiveness remains limited once tumors progress to advanced metastatic  \nThis is an open access article under the terms of the Creative Commons Attribution License, which p","cbCaiuy2GMMqBlGI","https://ap.wps.com/l/cbCaiuy2GMMqBlGI","pdf",11287530,28,"English","# Abstract\n# Introduction","[{\"question\":\"Why is targeted extracellular vesicle delivery important for ovarian cancer?\",\"answer\":\"Ovarian cancer is difficult to treat because of late detection, heterogeneity, and inadequate delivery of therapies to advanced tumors. The document emphasizes that off-target toxicity, rapid systemic clearance, and poor accumulation limit conventional approaches.\"},{\"question\":\"How does the engineered EV system achieve molecular targeting?\",\"answer\":\"The approach modifies the transmembrane scaffold Δ688 PTGFRN to display the tissue-targeting ligand Ephrin-B2 (EB2). This enables high-affinity interaction with Eph receptor B4 (EphB4), which is overexpressed in advanced ovarian carcinoma.\"},{\"question\":\"What evidence of selective delivery is reported in the patient-derived xenograft models?\",\"answer\":\"In xenografts with differential EphB4 expression, Ephrin-B2–displaying engineered EVs show selective localization to EphB4-positive tumors and can report intratumoral cargo distribution using bioluminescence tracking.\"}]","Scalable Engineering of Bio-Manufactured Extracellular Vesicles for Selective Delivery in Ovarian Cancer Patient-Derived Models | PDF",1790130128,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/86ddee179793eedafbee927b411abf9c.webp",983,1283,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/eb399d397f028440341269cada5258ee.webp",982,1281,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c6a914b300e0863752316cf8518dd282.webp",981,1280,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7494daaf04bee1df57507d4b7efd05a6.webp",980,1279]